Key result
Elevated serum cystatin C is linked to ~34% higher CAD risk per /l increase.
Observational (n=305)
Answers are grounded in this paper and cite their sources.
Demonstrates that serum cystatin C levels correlate with coronary artery disease severity in cardiac patients, indicating utility as a predictive biomarker.
BACKGROUND: Cystatin C has been proposed as a novel marker of renal function and predictor of cardiovascular risk. The aim of this study was to investigate the role of cystatin C level as a predictor of cardiovascular events in patients with coronary artery disease (CAD). METHODS: Three hundred and five coronary artery patients were included in this study. Serum cystatin C levels, high-sensitive C-reactive protein (hs-CRP), and oxidative stress were measured. Estimated glomerular filtration rate (eGFR) and the CAD severity score were calculated. RESULTS: Cystatin C was correlated with the CAD severity score (r = 0.631, P < 0.0001) and was significantly elevated in the CAD severity score >50. Every 0.1 mg/l increase in cystatin C, 2 mg/l increase in hs-CRP, 0.2 mmol/l decrease in high-density lipoprotein cholesterol, 13.7 ml/min decrease in eGFR, and 1.51 μmol/l increase in homocysteine caused a 34, 12, 5, and 22% increase in the risk of having CAD, respectively. CONCLUSION: Cystatin C could be a useful laboratory biochemical marker in predicting the severity of CAD. Cystatin C is associated with biochemical atherosclerosis markers such as CRP and homocysteine.
No takes yet. Share an insight, caveat, or question.
Dandana et al. (2014) conducted an observational in Coronary artery disease without chronic kidney disease (n=305). Serum cystatin C was evaluated on CAD severity score and risk of having CAD (r = 0.631, p=<0.0001). Serum cystatin C correlated with CAD severity, with each /l increase raising CAD risk by 34%.
Synapse has enriched 10 related papers. Consider them for comparative context: